Denosumab and zoledronic acid therapy improves BMD in periprosthetic bone

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-06-20 04:00 GMT   |   Update On 2023-06-20 07:03 GMT
Advertisement

A new study by Xiao Li and team showed that denosumab and zoledronic acid (ZA) are effective treatments against decline in periprosthetic bone mineral density. The findings of this study were published in Archives of Osteoporosis.

Following a total hip arthroplasty (THA), periprosthetic bone mineral density (BMD) loss may endanger the longevity of implants. By suppressing osteoclast activity, zoledronic acid and denosumab were successful in lowering bone loss in diseases linked to rapid bone turnover. In order to evaluate the effectiveness and safety of ZA and denosumab for periprosthetic BMD loss following THA, a meta-analysis was conducted.

Advertisement

MEDLINE, Embase, PubMed, the Cochrane Central Register of Controlled Trials, and the Web of Science were all thoroughly searched from 1980 to 2022 for randomized controlled trials (RCTs) including ZA or denosumab with THA. The Cochrane Review Manager 5 (RevMan) version 5.41 carried out the meta-analysis. For methodological quality and overall evidence quality, the Cochrane Risk of Bias Tool and GRADEpro were used, respectively.

The key findings of this study were:

1. Finally, 480 individuals from nine RCTs were enrolled and examined.

2. The patients in the intervention group experienced significantly less periprosthetic BMD loss in Gruen zone 7 at 3 months (MD = 4.30, 95% CI: 1.78-6.82, P = 0.0008), 6 months (MD = 7.71, 95% CI: 5.41-10.02, P 0.00001), and 12 months (MD = 8.19, 95% CI: 5.97-10.42,P < 0.00001) after THA than the patients in the control group.

3. There were no reported severe adverse events (AEs).

The authors advocate ZA or denosumab therapy for periprosthetic bone mineral density loss in the present study based on evidence on the effectiveness and safety of ZA and denosumab.

Reference:

Li, X., Han, J., Shi, X., Bi, Z., & Liu, J. (2023). Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. In Archives of Osteoporosis (Vol. 18, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1007/s11657-023-01227-9

Tags:    
Article Source : Archives of Osteoporosis

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News